000277477 001__ 277477
000277477 005__ 20240918112344.0
000277477 0247_ $$2doi$$a10.1186/s12933-023-01892-7
000277477 0247_ $$2pmid$$apmid:37438755
000277477 037__ $$aDKFZ-2023-01398
000277477 041__ $$aEnglish
000277477 082__ $$a610
000277477 1001_ $$aRhein, Sina$$b0
000277477 245__ $$aGlyoxal in hyperglycaemic ischemic stroke - a cohort study.
000277477 260__ $$aLondon$$bBioMed Central$$c2023
000277477 3367_ $$2DRIVER$$aarticle
000277477 3367_ $$2DataCite$$aOutput Types/Journal article
000277477 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726651404_5616
000277477 3367_ $$2BibTeX$$aARTICLE
000277477 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277477 3367_ $$00$$2EndNote$$aJournal Article
000277477 520__ $$aHyperglycaemia is frequent in acute ischemic stroke and denotes a bad prognosis, even in the absence of pre-existing diabetes. However, in clinical trials treatment of elevated glucose levels with insulin did not improve stroke outcome, suggesting that collateral effects rather than hyperglycaemia itself aggravate ischemic brain damage. As reactive glucose metabolites, glyoxal and methylglyoxal are candidates for mediating the deleterious effects of hyperglycaemia in acute stroke.In 135 patients with acute stroke, we used liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) to measure glyoxal, methylglyoxal and several of their glycated amino acid derivatives in serum. Results were verified in a second cohort of 61 stroke patients. The association of serum concentrations with standard stroke outcome scales (NIHSS, mRS) was tested.Glucose, glyoxal, methylglyoxal, and the glyoxal-derived glycated amino acid Nδ-(5-hydro-4-imidazolon-2-yl)ornithine (G-H1) were positively correlated with a bad stroke outcome at 3 months as measured by mRS90, at least in one of the two cohorts. However, the glycated amino acids Nε-carboxyethyllysine (CEL) and in one cohort pyrraline showed an inverse correlation with stroke outcome probably reflecting lower food intake in severe stroke. Patients with a poor outcome had higher serum concentrations of glyoxal and methylglyoxal.The glucose-derived α-dicarbonyl glyoxal and glycated amino acids arising from a reaction with glyoxal are associated with a poor outcome in ischemic stroke. Thus, lowering α-dicarbonyls or counteracting their action could be a therapeutic strategy for hyperglycaemic stroke.
000277477 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000277477 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277477 650_7 $$2Other$$aAdvanced glycation end-products
000277477 650_7 $$2Other$$aGlucose
000277477 650_7 $$2Other$$aIschemic brain damage
000277477 650_7 $$2Other$$aUndernutrition
000277477 7001_ $$aInderhees, Julica$$b1
000277477 7001_ $$aHerrmann, Oliver$$b2
000277477 7001_ $$aOthman, Alaa$$b3
000277477 7001_ $$aBegemann, Kimberly$$b4
000277477 7001_ $$aFleming, Thomas$$b5
000277477 7001_ $$aNawroth, Peter P$$b6
000277477 7001_ $$0P:(DE-He78)c53db83479d3d1265967405af71f69bb$$aKlika, Karel$$b7$$udkfz
000277477 7001_ $$aIsa, Rakad$$b8
000277477 7001_ $$aKönig, Inke R$$b9
000277477 7001_ $$aRoyl, Georg$$b10
000277477 7001_ $$00000-0002-4510-9718$$aSchwaninger, Markus$$b11
000277477 773__ $$0PERI:(DE-600)2093769-6$$a10.1186/s12933-023-01892-7$$gVol. 22, no. 1, p. 173$$n1$$p173$$tCardiovascular diabetology$$v22$$x1475-2840$$y2023
000277477 909CO $$ooai:inrepo02.dkfz.de:277477$$pVDB
000277477 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c53db83479d3d1265967405af71f69bb$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000277477 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000277477 9141_ $$y2023
000277477 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-17
000277477 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-17
000277477 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-17
000277477 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-17
000277477 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCARDIOVASC DIABETOL : 2022$$d2023-10-24
000277477 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000277477 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000277477 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000277477 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:07:21Z
000277477 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:07:21Z
000277477 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:07:21Z
000277477 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000277477 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000277477 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000277477 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000277477 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000277477 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCARDIOVASC DIABETOL : 2022$$d2023-10-24
000277477 9201_ $$0I:(DE-He78)W160-20160331$$kW160$$lMolekulare Strukturanalyse$$x0
000277477 980__ $$ajournal
000277477 980__ $$aVDB
000277477 980__ $$aI:(DE-He78)W160-20160331
000277477 980__ $$aUNRESTRICTED